4.8 Review

Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?

期刊

JOURNAL OF HEPATOLOGY
卷 78, 期 6, 页码 1124-1129

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2023.03.032

关键词

Hepatocellular carcinoma; Liver transplantation; Portal vein tumour thrombosis; Transplant benefit; Segmental and lobar PVTT; Downstaging modalities

向作者/读者索取更多资源

In this debate, the authors discuss the suitability of liver transplantation for patients with hepatocellular carcinoma and portal vein tumor thrombosis. The argument for liver transplantation is based on the belief that it provides greater clinical benefits in terms of survival outcomes compared to palliative systemic therapy after successful downstaging treatment. The counterargument is that the evidence for liver transplantation in this setting is limited, and expected survival in these patients may still be lower than the accepted thresholds for liver transplantation.
In this debate, the authors consider whether patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombosis are candidates for liver transplantation (LT). The argument for LT in this context is based on the premise that, following successful downstaging treatment, LT confers a much greater clinical benefit in terms of survival outcomes than the available alternative (palliative systemic therapy). A major argument against relates to limitations in the quality of evidence for LT in this setting - in relation to study design, as well as heterogeneity in patient characteristics and downstaging protocols. While acknowledging the superior outcomes offered by LT for patients with portal vein tumour thrombosis, the counterargument is that expected survival in such patients is still below accepted thresholds for LT and, indeed, the levels achieved for other patients who receive transplants beyond the Milan criteria. Based on the available evidence, it seems too early for consensus guidelines to recommend such an approach, however, it is hoped that with higher quality evidence and standardised downstaging protocols, LT may soon be more widely indicated, including for this population with high unmet clinical need. (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据